Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
European Commission approves Rezolsta ® , a new once - daily , fixed - dose HIV therapy combining darunavir and cobicistat

Janssen-Cilag International NV (Janssen) today announced that the European Commission (EC) has approved the use of REZOLSTA ® (darunavir/cobicistat) in combination with other antiretroviral (ARV) medicinal products for the treatment of human immunodeficiency virus - 1 (HIV - 1) infection in adults aged 18 years or older. "REZOLSTA ® eliminates the need to take a boosting agent in a separate tablet with once - daily darunavir, reducing the pill burden for patients," said Christiane Moecklinghoff, M.D Ph.D, Medical Director, Virology, Janssen EMEA.

Published
15 hours ago
From
Janssen
Zimbabwe: Stealing Lives

Exposing the trade in stolen drugs that is costing the lives of tens of thousands of HIV/AIDS sufferers in Zimbabwe.

Published
24 November 2014
From
Al Jazeera (video)
CHMP Grants Positive Opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe

Major regulatory milestone achieved toward approval in the European Union; final decision from the European Commission expected in the first quarter of 2015.

Published
21 November 2014
From
AbbVie press release
Pharmaceutical Industry Doing More to Improve Access to Medicine in Developing Countries; Performance on Some Aspects Lags

The world's leading pharmaceutical companies are doing more to improve access to medicine in developing countries, with a raft of new initiatives, scale-ups and innovations over the last two years. However, the industry struggles to perform well in some practices that matter, according to the 2014 Access to Medicine Index, published Monday. GSK tops the Index for the fourth time. This is driven by robust performance across most areas, with several innovative practices. Novo Nordisk has made the most progress, improving in five of the seven areas the Index focuses on. This has resulted in a remarkable leap from 6th to 2nd place. Sanofi and Pfizer fell down the ranking most significantly.

Published
18 November 2014
From
Access to Medicine Index
HIV Drug Development Pipeline Update, Fall 2014 Edition

HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. At IDWeek 2014 in Philadelphia, Paul Sax, M.D., made the case for this new generation of drugs, and provided an update on several of the most noteworthy candidates currently in development.

Published
17 November 2014
From
The Body Pro
Merck’s four-week treatment for hepatitis C misses the mark

In disappointing news for Merck, the drug maker released results of an interim study showing a triple combination treatment – which includes two of its own compounds and the big-selling Sovaldi medication from Gilead Sciences – came up short.

Published
11 November 2014
From
Wall Street Journal
HIV generics in the U.S.: Sooner or later?

Why do we continue to spend billions of dollars for brand-name drugs that are available in cheaper generic forms in the developing world -- billions that end up as profits for pharmaceutical industry?

Published
10 November 2014
From
The Body
Innovation in fixed-dose combos: HIV/AIDS therapeutics edition

FDC drug development is evolving rapidly as the industry gains experience in manufacturing them and ushering them through the review process. The laws have changed towards a more favorable marketing climate. And finally, it is clear that FDCs are more than a way to improve adherence—though that will always be a prominent consideration. FDCs can shift the standard of care towards a more tolerable, patient-friendly, value-oriented approach to treatment, and in the final analysis, that approach to development bodes well for companies, payers, and most importantly, patients.

Published
07 November 2014
From
BioPharma Dive
Bristol-Myers Plan to Widen Access to its Hep C Drug is Criticized

“Unfortunately, history seems to be repeating itself with BMS, who hasn’t learned from the company’s poor track record responding to the HIV epidemic,” says Rohit Malpani of Doctors Without Borders.

Published
05 November 2014
From
Wall Street Journal
Generic antiretrovirals could save NHS £1.25 billion over 5 years, study finds

Switching all patients taking antiretrovirals in the United Kingdom to generic versions of the drugs they are taking, if available, would save around £1.25 billion between 2015 and

Published
04 November 2014
By
Michael Carter
← First12345...70Next →

Filter by country